Scott VandenBerg, MD, PhD

Scott VandenBerg, MD, PhD

Director, Tissue Core Facility, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 514-4978
UCSF Box 0875
San Francisco, CA 94143-0875

UCSF Profiles

Cancer Center Membership

Member » Non-aligned

Research Summary

I have extensive experience with developing tissue-based biomarker techniques and with directing biorepositories for the optimal acquisition, archiving, annotation, and custodianship of human tissue for cancer research. The techniques that I have expertise with in molecular morphology include immunohistochemistry / immunofluorescence and molecular in situ analyses. A major emphasis of my technical research core activities since 2008 has been to develop more quantitative detection of biomarkers of activated signaling pathways in a wide spectrum of human disease, focusing on cancer. My translational research focuses on the application of multiple proteomic, epigenetic and genetic techniques for the molecular morphologic analysis of biomarkers in CNS tumor sections. The technologies include processing techniques for tissue to preserve analyte quality for RNA, DNA and proteomics with optimal histologic quality and multiple detection modalities on tissue sections for biomarker multiplexing in heterogeneous tumors, including the genomic and proteomic characterization of prognostic markers in CNS tumors. I directed the establishment of a tissue technology laboratory to optimize the use of quantitative immunofluorescence detection techniques for combined IF/ISH analyses and for the multiplex analysis of inter-related signaling pathways in human tissue, focusing on cancer. Before coming to UCSF, I was Director of the UCSD Moores Comprehensive Center Biorepository, Histopathology, and Tissue Technology Shared Resource in 2012-2015.


Duke University, BS, 1968-1972, Zoology
Stanford University School of Medicine, MD, PhD, 1968-1972, Medicine/Neurosciences
University of Colorado, Intern, 1979-1980, Pathology
Stanford University School of Medicine, Postdoctoral Fellow, 1980-1982, Neurochemistry/Neuropathology
University of Virginia, Residency Fellowship, 1982-1984, Pathology/Neuropathology

Professional Experience

  • 1984-1990
    Assistant Professor of Pathology, University of Virginia School of Medicine
  • 1984-2003
    Faculty of the Neurosciences Graduate Program, University of Virginia School of Medicine
  • 1990-2003
    Director of Neuropathology, Neuropathology Training Program Director, Department of Pathology, University of Virginia School of Medicine
  • 1990-1993
    Associate Professor of Pathology (with tenure), University of Virginia School of Medicine
  • 1994-2003
    Professor of Pathology and Neurological Surgery, University of Virginia School of Medicine
  • 1994-2003
    Division Head, Neuropathology, University of Virginia School of Medicine
  • 1998-2003
    Medical Director of Neuropathology Lab Services, Director of the Special Tissues Laboratory, University of Virginia School of Medicine
  • 1998-2003
    John T. and Louise Nerancy Professor of Neurosciences, University of Virginia School of Medicine
  • 2003-2009
    Professor, Departments of Pathology and Neurological Surgery, UCSF
  • 2004-2009
    Director, UCSF Brain Tumor Research Center Tissue Core
  • 2006-2009
    Director, UCSF Neuropathology Biomarkers Laboratory 2009-07/2015 Professor (Step VI), Department of Pathology, UCSD
  • 2009-07/2015
    Director of Neuropathology, UCSD
  • 2009-07/2015
    Director CTRI Human Tissue Resources, UCSD
  • 2009-07/2015
    Director Laboratory for Human Tissue Technology, UCSD
  • 2012-07/2015
    Director, Biorepository, Histopathology, and Tissue Technology Shared Resource, UCSD MCC
  • 07/2015
    Director of the UCSF Biospecimen Resources (BIOS) Program

Honors & Awards

  • 1971
    Phi Beta Kappa, Junior Year Election, Duke University
  • 1972
    Graduation Summa Cum Laude with Distinction in Zoology, Duke University
  • 1972
    Edward C. Horn Memorial Prize for Excellence in Zoology
  • 1974
    Weil Award, American Association of Neuropathologists
  • 1974-1976
    Scholar of the Insurance Medical Scientist Fund, Stanford University School of Medicine
  • 1990
    Charter Member, Diagnostic Slide Session of the American Association of Neuropathologists
  • 2003-2004
    Vice President, American Association of Neuropathologists

Selected Publications

  1. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YY, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2016 Dec 08.
    View on PubMed
  2. Sheth V, Shao H, Chen J, Vandenberg S, Corey-Bloom J, Bydder GM, Du J. Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: Phantom, specimen, volunteer and multiple sclerosis patient studies. Neuroimage. 2016 Aug 1; 136:37-44.
    View on PubMed
  3. van Vugt VA, Kesari A, Muller KA, Carter B, Vandenberg SR, Kesari S. A 22-Year Old Woman with Right Eyelid Swelling. Brain Pathol. 2016 May; 26(3):425-6.
    View on PubMed
  4. Jones KA, Gilder AS, Lam MS, Du N, Banki MA, Merati A, Pizzo DP, VandenBerg SR, Gonias SL. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. Neuro Oncol. 2016 May; 18(5):667-78.
    View on PubMed
  5. Barajas RF, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha S. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015 Oct; 70(10):1087-95.
    View on PubMed
  6. Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, Mao Y, Kwon CH, Saya H, Nakano I, Pizzo DP, VandenBerg SR, Chen CC. Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. Proc Natl Acad Sci U S A. 2015 Jul 28; 112(30):E4055-64.
    View on PubMed
  7. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View on PubMed
  8. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2015 Jan 15; 75(2):394-404.
    View on PubMed
  9. Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 2015 Jul 30; 34(31):4078-88.
    View on PubMed
  10. Li J, Taich ZJ, Goyal A, Gonda D, Akers J, Adhikari B, Patel K, Vandenberg S, Yan W, Bao Z, Carter BS, Wang R, Mao Y, Jiang T, Chen CC. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014 Sep 15; 5(17):7342-56.
    View on PubMed
  11. Farid N, Almeida-Freitas DB, White NS, McDonald CR, Kuperman JM, Almutairi AA, Muller KA, VandenBerg SR, Kesari S, Dale AM. Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). J Neurooncol. 2014 Dec; 120(3):539-46.
    View on PubMed
  12. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7.
    View on PubMed
  13. Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014 Jul 24; 511(7510):428-34.
    View on PubMed
  14. Mahta A, Borys E, Vandenberg SR, Carter B, Kesari S. 72 year old female with leg weakness. Brain Pathol. 2014 Mar; 24(2):195-6.
    View on PubMed
  15. Du J, Ma G, Li S, Carl M, Szeverenyi NM, VandenBerg S, Corey-Bloom J, Bydder GM. Ultrashort echo time (UTE) magnetic resonance imaging of the short T2 components in white matter of the brain using a clinical 3T scanner. Neuroimage. 2014 Feb 15; 87:32-41.
    View on PubMed
  16. Mahta A, Du Z, Borys E, Carter B, Vandenberg SR, Kesari S. 78 year old male with dysphagia and dysarthria. Brain Pathol. 2013 Nov; 23(6):705-6.
    View on PubMed
  17. Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4530-9.
    View on PubMed
  18. Farid N, Almeida-Freitas DB, White NS, McDonald CR, Muller KA, Vandenberg SR, Kesari S, Dale AM. Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. Front Oncol. 2013; 3:258.
    View on PubMed
  19. Garmy-Susini B, Avraamides CJ, Desgrosellier JS, Schmid MC, Foubert P, Ellies LG, Lowy AM, Blair SL, Vandenberg SR, Datnow B, Wang HY, Cheresh DA, Varner J. PI3Ka activates integrin a4ß1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A. 2013 May 28; 110(22):9042-7.
    View on PubMed
  20. Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, VandenBerg SR, Gonias SL. Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res. 2013 Jul 1; 73(13):3902-12.
    View on PubMed

Go to UCSF Profiles, powered by CTSI